NICE Recommends Ferring Pharmaceutical’s Firmagon for Prostate Cancer
The UK’s drug pricing watchdog is recommending reimbursement of Ferring Pharmaceutical’s prostate cancer treatment Firmagon, provided that the company lowers its prices.
In a final appraisal, UK’s National Institute for Health and Care Excellence deemed the therapy equal to first-line treatments for hormone-dependent prostate cancer, such as leuprorelin, goserelin and triptorelin. Six randomized, open-label studies were the basis for this conclusion.
Without the discount, a course of treatment is priced at $16,319. The guidance did not specify the recommended discount amount.